Onychomycosis (fungal toenails) affects 30-50% of adults with diabetes compared with 10% of general adults — a 3-5 fold elevation in prevalence. The mechanisms involve impaired immune function from hyperglycemia, reduced peripheral circulation, warm moist shoe environments, slower nail growth, and concurrent athlete’s foot infection. Treatment is harder in diabetes than in non-diabetic adults — reduced foot blood flow delivers oral medication less effectively, and topical treatments penetrate thickened diabetic nails less well. Recurrence rates of 25-50% are common. The diabetes-specific concern isn’t the cosmetic appearance but the secondary risks — thickened deformed nails increase ingrown nail risk, fungal nails can serve as reservoirs for bacterial infection, and underlying immune dysfunction makes progression more likely. For most adults with diabetes, treatment is worthwhile despite the challenges.
What Is Onychomycosis?
- Fungal infection of the toenail (or fingernail).
- Most commonly caused by dermatophyte fungi (Trichophyton rubrum).
- Symptoms: thickening, discoloration (yellow, brown, white), crumbling, distortion of nail shape.
- Pain in advanced cases due to pressure of thickened nail against shoe.
- Usually starts at the nail tip and progresses to the cuticle.
Treatment Options
| Treatment | Duration | Cure rate | Diabetes notes |
|---|---|---|---|
| Oral terbinafine | 12 weeks | 60-70% | LFTs needed; drug interactions |
| Oral itraconazole pulse | 3 months | 50-60% | More drug interactions |
| Topical efinaconazole (Jublia) | 48 weeks | 15-25% | No systemic exposure |
| Topical tavaborole (Kerydin) | 48 weeks | 15-25% | No systemic exposure |
| Laser treatment | 3-4 sessions | Variable | FDA-cleared; expensive; out-of-pocket |
| Surgical nail avulsion | Single procedure | High initial; recurrence common | For severe pain or refractory cases |
Why Treatment Is Harder in Diabetes
- Reduced foot blood flow delivers oral medication less effectively to nails.
- Thickened nails in diabetes resist topical penetration.
- Slower nail growth means longer treatment needed.
- Impaired immune function reduces fungal clearance.
- Concurrent athlete’s foot maintains fungal reservoir.
- Higher recurrence rates after successful treatment.
The Diabetes-Specific Concerns
- Thickened deformed nails increase ingrown toenail risk.
- Fungal nails serve as reservoir for skin infections (athlete’s foot, cellulitis).
- Severe cases cause pain and gait alteration.
- Adults with peripheral neuropathy may not notice progression.
- Pressure of thickened nails against shoes can cause ulcers.
- The cosmetic concern is secondary to the functional risks.
Prevention
- Treat concurrent athlete’s foot promptly.
- Trim nails straight across.
- Disinfect shoe interiors regularly.
- Alternate shoes daily for drying.
- Wear moisture-wicking socks.
- Avoid going barefoot in public showers, pools.
- Use antifungal foot powder daily.
- Maintain glucose control.
- Annual podiatric exam.
When to See a Podiatrist
- Visible nail thickening, discoloration, or distortion that concerns you.
- Pain when wearing shoes due to nail thickness.
- Ingrown nail edges developing alongside the fungal nail.
- Bleeding or oozing from around the nail.
- Concurrent athlete’s foot or skin infection.
- Adults with peripheral neuropathy should have annual podiatric examination regardless of symptoms.
- Adults considering oral antifungal medication need pre-treatment liver function tests.
- Adults on multiple medications need drug interaction review before starting terbinafine or itraconazole.
- Severe cases where nail removal may be considered for comfort or function.
The Bottom Line
Onychomycosis affects 30-50% of adults with diabetes vs 10% of general adults — a 3-5 fold elevation. The mechanisms involve impaired immune function, reduced peripheral circulation, warm moist shoe environments, and slower nail growth. Treatment is harder in diabetes — oral terbinafine (12-week course, 60-70% cure rate) is first-line but requires LFT monitoring and has drug interactions; topical efinaconazole and tavaborole (48-week courses, 15-25% cure rates) avoid systemic exposure but penetrate diabetic nails poorly. Laser treatment is FDA-cleared but expensive. Recurrence rates of 25-50% are common, particularly with concurrent athlete’s foot. The diabetes-specific concern is functional: thickened deformed nails increase ingrown nail and skin infection risks. For adults with diabetes, treatment is worthwhile despite challenges, particularly with concurrent foot fungal infections, pain, or ingrown nail risk. Prevention through athlete’s foot treatment, proper nail care, shoe hygiene, and glucose control reduces recurrence. See our broader ingrown toenails and diabetes guide for context on the functional complications.
